



## **About Oryzon**

Oryzon is a biopharmaceutical company, based in Barcelona (Spain) and Cambridge, Massachusetts, which develops pharmaceutical products. Oryzon conducts research independently through its R&D department, but also via partnerships with other pharmaceutical companies. The company focuses on the discovery, research and development of new chemical entities, as well as conducting clinical trials. Oryzon's field of activity focuses preferentially on epigenetics in various therapeutic indications, with a special emphasis on oncology and neurodegenerative diseases.

Founded in 2000, Oryzon is listed on the Madrid Stock Exchange (ticker: ORY). It is a Spanish commercial company, and as such is governed by the Restated Text of the Companies Act approved by the Royal Legislative Decree, 1/2010 of July 2 (Texto Refundido de la Ley de Sociedades de Capital, aprobado mediante Real Decreto Legislativo 1/2010, de 2 de julio) (the "Companies Act"), and other applicable legislation, as well as by the specific regulation of its sector.

For more information, please visit [www.oryzon.com](http://www.oryzon.com)